company background image
BUWA logo

Bio-Rad Laboratories DB:BUWA Stock Report

Last Price

€312.50

Market Cap

€8.9b

7D

-2.3%

1Y

8.0%

Updated

25 Dec, 2024

Data

Company Financials +

Bio-Rad Laboratories, Inc.

DB:BUWA Stock Report

Market Cap: €8.9b

BUWA Stock Overview

Manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. More details

BUWA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Bio-Rad Laboratories, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Bio-Rad Laboratories
Historical stock prices
Current Share PriceUS$312.50
52 Week HighUS$351.80
52 Week LowUS$244.70
Beta0.90
1 Month Change-1.70%
3 Month Change10.62%
1 Year Change7.98%
3 Year Change-52.65%
5 Year Change-4.14%
Change since IPO1,336.78%

Recent News & Updates

Recent updates

Shareholder Returns

BUWADE Life SciencesDE Market
7D-2.3%-1.4%-1.6%
1Y8.0%-5.5%6.8%

Return vs Industry: BUWA exceeded the German Life Sciences industry which returned -5.6% over the past year.

Return vs Market: BUWA exceeded the German Market which returned 6.8% over the past year.

Price Volatility

Is BUWA's price volatile compared to industry and market?
BUWA volatility
BUWA Average Weekly Movement5.2%
Life Sciences Industry Average Movement7.1%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: BUWA has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: BUWA's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19528,030Norman Schwartzwww.bio-rad.com

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

Bio-Rad Laboratories, Inc. Fundamentals Summary

How do Bio-Rad Laboratories's earnings and revenue compare to its market cap?
BUWA fundamental statistics
Market cap€8.88b
Earnings (TTM)-€749.02m
Revenue (TTM)€2.48b

3.6x

P/S Ratio

-11.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BUWA income statement (TTM)
RevenueUS$2.58b
Cost of RevenueUS$1.17b
Gross ProfitUS$1.41b
Other ExpensesUS$2.19b
Earnings-US$778.69m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-27.81
Gross Margin54.54%
Net Profit Margin-30.18%
Debt/Equity Ratio15.9%

How did BUWA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 08:26
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bio-Rad Laboratories, Inc. is covered by 27 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Jon WoodBofA Global Research
Sel HardyCFRA Equity Research